Results 91 to 100 of about 365,681 (229)

Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer

Cancer Management and Research
Yeasin Ahamed,1,2 Lichao Wu,1 Shantanu Baral,1 Ashab Uddin Al-Raiyan,1 Weigui Sun1,2 1Department of Urology Surgery, The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225001, People’s Republic of China; 2Clinical Medical College ...
Ahamed Y, Wu L, Baral S, Al-Raiyan AU, Sun W   +4 more
doaj  

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1

Asian Journal of Andrology, 2015
Percent free prostatic-specific antigen (%fPSA) has been introduced as a tool to avoid unnecessary biopsies in patients with a serum PSA level of 4.0-10.0 ng ml−1 , however, it remains controversial whether %fPSA is effective in PSA range of 10.1-20.0 ng
Rui Chen, Li-Qun Zhou, Xiao-Bing Cai, Li-Ping Xie, Yi-Ran Huang, Da-Lin He, Xu Gao, Chuan-Liang Xu, Qiang Ding, Qiang Wei, Chang-Jun Yin, Shan-Cheng Ren, Fu-Bo Wang, Ye Tian, Zhong-Quan Sun, Qiang Fu, Lu-Lin Ma, Jun-Hua Zheng, Zhang-Qun Ye, Ding-Wei Ye, Dan-Feng Xu, Jian-Quan Hou, Ke-Xin Xu, Jian-Lin Yuan, Xin Gao, Chun-Xiao Liu, Tie-Jun Pan, Ying-Hao Sun, on behalf of Chinese Prostate Cancer Consortium   +28 more
doaj   +1 more source

Response: Re: An Empirical Evaluation of Guidelines on Prostate-Specific Antigen Velocity in Prostate Cancer Detection [PDF]

, 2011
Andrew J. Vickers, Cathee Till
openalex   +1 more source

Genomic biomarkers in prostate cancer. [PDF]

, 2018
Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer.
Cooperberg, Matthew R, Feng, Felix Y, Kornberg, Zachary, Spratt, Daniel E   +3 more
core  

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide

BMC Research Notes, 2018
Objective The objective of this retrospective study was to evaluate whether the effect of second-line therapy of flutamide after bicalutamide can predict the response to abiraterone.
Yasushi Nakai, Nobumichi Tanaka, Makito Miyake, Takeshi Inoue, Satoshi Anai, Kiyohide Fujimoto   +5 more
doaj   +1 more source

Editorial Comment from Dr Mearini to Postoperative prostate‐specific antigen monitoring interval for radical prostatectomy patients with low recurrence risk [PDF]

, 2015
Luigi Mearini
openalex   +1 more source

Comparison of the Diagnostic Performance of Multiparametric Prostate Magnetic Resonance Imaging Results with Classical Parameters for Prostate Carcinoma in Gray Zone Patients

Journal of Urological Surgery
Objective: To compare the diagnostic value of prostate imaging-reporting and data system (mpMRI) version 2.0 with classical parameters for prostate cancer detection in gray zone patients with ultrasonography-guided prostate biopsy as a reference point ...
Coşkun Bostancı, Demirhan Örsan Demir
doaj   +1 more source

Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness

Tumor Biology, 2019
Prostate cancer represents a major cause of cancer death in men worldwide. Novel non-invasive methods are still required for differentiation of non-aggressive from aggressive tumors.
Robert Lang, Vinzent Rolny, Andreas Leinenbach, Johann Karl, Magdalena Swiatek-de Lange, Uwe Kobold, Mark Schrader, Hans Krause, Markus Mueller, Michael Vogeser   +9 more
doaj   +1 more source

A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA) [PDF]

, 2011
Sangeeta Ray Banerjee, Mrudula Pullambhatla, Hassan M. Shallal, Ala Lisok, Ronnie C. Mease, Martin G. Pomper   +5 more
openalex   +1 more source

Movie S4 from Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies

, 2023
Jessica Matthias, Johann Engelhardt, Martin Schäfer, Ulrike Bauder‐Wüst, Philipp T. Meyer, Uwe Haberkorn, Matthias Eder, Klaus Kopka, Stefan W. Hell, Ann-Christin Eder   +9 more
openalex   +1 more source